Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie Sells 3,000 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 3,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Axsome Therapeutics Trading Down 0.4 %

NASDAQ:AXSM opened at $131.15 on Friday. The firm has a 50-day simple moving average of $97.84 and a 200-day simple moving average of $93.27. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $134.18. The firm has a market cap of $6.36 billion, a P/E ratio of -20.08 and a beta of 1.05. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -4.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on AXSM. Wells Fargo & Company upped their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a research note on Monday, February 10th. Royal Bank of Canada reissued an “outperform” rating and set a $139.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Robert W. Baird upped their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners increased their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $147.13.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Pitcairn Co. increased its position in shares of Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock worth $386,000 after purchasing an additional 148 shares in the last quarter. Meridian Wealth Management LLC boosted its position in shares of Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock worth $1,791,000 after purchasing an additional 150 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Axsome Therapeutics by 4.4% during the 4th quarter. Ameritas Investment Partners Inc. now owns 3,852 shares of the company’s stock worth $326,000 after buying an additional 162 shares during the last quarter. Arizona State Retirement System increased its position in Axsome Therapeutics by 1.8% during the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock valued at $766,000 after buying an additional 164 shares in the last quarter. Finally, Intrust Bank NA raised its stake in Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock valued at $239,000 after buying an additional 183 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.